HK1134455A1 - Attenuation of vasoactive oxygen carrier-induced vasoconstriction - Google Patents

Attenuation of vasoactive oxygen carrier-induced vasoconstriction

Info

Publication number
HK1134455A1
HK1134455A1 HK10102533.8A HK10102533A HK1134455A1 HK 1134455 A1 HK1134455 A1 HK 1134455A1 HK 10102533 A HK10102533 A HK 10102533A HK 1134455 A1 HK1134455 A1 HK 1134455A1
Authority
HK
Hong Kong
Prior art keywords
attenuation
oxygen carrier
induced vasoconstriction
vasoactive oxygen
vasoactive
Prior art date
Application number
HK10102533.8A
Other languages
English (en)
Chinese (zh)
Inventor
Warren M Zapol
Binglan Yu
Fumito Ichinose
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1134455(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of HK1134455A1 publication Critical patent/HK1134455A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
    • A61M16/1015—Preparation of respiratory gases or vapours with O2 features or with parameter measurement using a gas flush valve, e.g. oxygen flush valve
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/208—Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A61M2016/0039—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
    • A61M2016/102—Measuring a parameter of the content of the delivered gas
    • A61M2016/1035—Measuring a parameter of the content of the delivered gas the anaesthetic agent concentration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0266—Nitrogen (N)
    • A61M2202/0275—Nitric oxide [NO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK10102533.8A 2006-11-07 2010-03-11 Attenuation of vasoactive oxygen carrier-induced vasoconstriction HK1134455A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86473406P 2006-11-07 2006-11-07
PCT/US2007/083746 WO2008063868A2 (fr) 2006-11-07 2007-11-06 Atténuation de la vasoconstriction induite par un transporteur d'oxygène vasoactif

Publications (1)

Publication Number Publication Date
HK1134455A1 true HK1134455A1 (en) 2010-04-30

Family

ID=39430446

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10102533.8A HK1134455A1 (en) 2006-11-07 2010-03-11 Attenuation of vasoactive oxygen carrier-induced vasoconstriction

Country Status (10)

Country Link
US (1) US8887721B2 (fr)
EP (2) EP2099463B1 (fr)
JP (2) JP5697335B2 (fr)
KR (2) KR20090087900A (fr)
CN (1) CN101573125B (fr)
AR (1) AR063604A1 (fr)
CL (1) CL2007003193A1 (fr)
HK (1) HK1134455A1 (fr)
TW (1) TWI474824B (fr)
WO (1) WO2008063868A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US20130266668A1 (en) * 2010-12-01 2013-10-10 Virginia Commonwealth University Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
JP5837044B2 (ja) * 2011-03-09 2015-12-24 テルモ株式会社 酸素運搬体投与システム、酸素運搬体酸素化装置および酸素運搬体用収容体
EP2729000B1 (fr) * 2011-07-05 2022-12-14 Hemanext Inc. Un procédé pour le stockage prolongé des érythrocytes
CN104159591A (zh) * 2011-11-07 2014-11-19 通用医疗公司 红细胞的处理
JP6104513B2 (ja) * 2012-03-09 2017-03-29 エア・ウォーター株式会社 人工呼吸器
US20130274245A1 (en) * 2012-04-11 2013-10-17 Jan BLUMENSTEIN Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia
FR2990858B1 (fr) * 2012-05-24 2015-04-03 Air Liquide Sante Int Melange gazeux no/azote a teneur elevee en no pour traiter les detresses respiratoires hypoxemiantes severes
WO2014134503A1 (fr) 2013-02-28 2014-09-04 New Health Sciences, Inc. Dispositifs d'appauvrissement de gaz et d'addition de gaz pour traitement sanguin
US10758700B2 (en) * 2013-09-30 2020-09-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Home-based heliox system with carbon dioxide removal
US20160271056A1 (en) * 2013-12-23 2016-09-22 Nitric Solutions Inc. Cystic fibrosis treatment comprising nitric oxide
WO2015106115A1 (fr) * 2014-01-10 2015-07-16 Ino Therapeutics Llc Méthdoes d'utilisation de monoxyde d'azote inhalé pour le traitement du syndrome de détresse respiratoire aiguë chez l'enfant
FR3017052B1 (fr) * 2014-01-31 2016-02-26 Air Liquide Sante Int Melange gazeux no/he a action bactericide
US10525226B2 (en) * 2014-05-14 2020-01-07 Mallinckrodt Hospital Products IP Limited Systems and methods for indicating lifetime of an NO2-to-NO reactor cartridge used to deliver NO for inhalation therapy to a patient
KR102701691B1 (ko) 2015-03-10 2024-08-30 헤마넥스트 인코포레이티드 산소 감소 1회용 키트, 장치 및 이의 사용 방법
CN107847395B (zh) 2015-04-23 2021-10-15 新健康科学股份有限公司 厌氧血液储存容器
BR122021024410B1 (pt) 2015-05-18 2022-05-03 Hemanext Inc Métodos para gerenciar um banco de sangue e para prover fornecimento de produtos de sangue total armazenados para medicina de transfusão
BR112018006600B1 (pt) * 2015-10-01 2022-05-17 Mallinckrodt Hospital Products IP Limited Dispositivo e método para difusão de no de alta concentração com gás para terapia de inalação
US10828436B2 (en) * 2016-04-05 2020-11-10 Vanderbilt University Administering the noble gas argon during cardiopulmonary resuscitation
IL303240A (en) 2016-05-27 2023-07-01 Hemanext Inc Anaerobic blood storage and pathogen inactivation method
MX2020010523A (es) 2017-02-27 2021-02-09 Third Pole Inc Sistemas y metodos para generar oxido nitrico.
MX2020001853A (es) * 2017-08-25 2020-08-03 Mallinckrodt Hospital Products Ip Ltd Métodos para mejorar la viabilidad de los órganos.
JP2022517788A (ja) * 2019-01-14 2022-03-10 ベレロフォン・セラピューティクス Ｐｄｅ－５阻害剤と吸入用一酸化窒素との併用薬物療法
WO2020185674A1 (fr) * 2019-03-08 2020-09-17 South Dakota Board Of Regents Composé topique vasoactif destiné à affecter le débit sanguin tissulaire, réduire la nécrose des tissus et favoriser la cicatrisation
US20210395905A1 (en) * 2020-06-18 2021-12-23 Third Pole, Inc. Systems and methods for preventing and treating infections with nitric oxide
WO2023049873A1 (fr) 2021-09-23 2023-03-30 Third Pole, Inc. Systèmes et procédés destinés à fournir de l'oxyde nitrique

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5536241A (en) * 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
SG47527A1 (en) * 1990-12-05 1998-04-17 Gen Hospital Corp Devices for treating pulmonary vasoconstriction and asthma
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
US5296466A (en) 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
EP0621051B1 (fr) * 1993-04-17 2001-08-22 MESSER GRIESHEIM AUSTRIA Ges.m.b.H. Appareil de contrôle du dosage en NO de l'air aspiré pour un patient
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
GB9320978D0 (en) * 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
SE9303486L (sv) * 1993-10-22 1995-04-23 Siemens Elema Ab Metod vid bestämning av den funktionella residualkapaciteten för lungor samt en ventilatoranordning för bestämning av den funktionella residualkapaciteten
US5558083A (en) * 1993-11-22 1996-09-24 Ohmeda Inc. Nitric oxide delivery system
SE503876C2 (sv) * 1994-11-30 1996-09-23 Kjell Alving Detektion av inflammatoriska tillstånd i tarmkanalen genom att mäta kväveoxidhalten i ett prov taget ur tarmlumen
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5823180A (en) * 1995-04-03 1998-10-20 The General Hospital Corporation Methods for treating pulmonary vasoconstriction and asthma
ATE331505T1 (de) * 1996-04-05 2006-07-15 Gen Hospital Corp Behandlung einer hämoglobinstörung
WO1998008500A1 (fr) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Compositions hypertoniques d'arginine et procedes
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US6656452B1 (en) * 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6089229A (en) * 1998-05-26 2000-07-18 Datex-Ohmeda, Inc. High concentration no pulse delivery device
US6139506A (en) * 1999-01-29 2000-10-31 Instrumentarium Oy Method for measuring pulmonary functional residual capacity
US6237594B1 (en) * 1999-09-22 2001-05-29 Salter Labs Pneumatically-operated gas demand apparatus
US6894150B1 (en) * 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
MXPA03012031A (es) 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
US6811778B2 (en) * 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock
ES2294543T3 (es) * 2003-07-09 2008-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
WO2005077005A2 (fr) 2004-02-04 2005-08-25 The General Hospital Corporation Amelioration de l'efficacite d'un gaz therapeutique inhale
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
CA2583073A1 (fr) 2004-10-05 2006-04-13 Bayer Healthcare Ag Stimulateur de guanylate cyclase et oxyde nitrique utiles dans le traitement de la bronchoconstriction et de la vasoconstriction pulmonaire
US7530353B2 (en) * 2005-09-21 2009-05-12 The General Electric Company Apparatus and method for determining and displaying functional residual capacity data and related parameters of ventilated patients

Also Published As

Publication number Publication date
WO2008063868A2 (fr) 2008-05-29
CN101573125B (zh) 2013-06-19
EP2099463A2 (fr) 2009-09-16
US20100051025A1 (en) 2010-03-04
AR063604A1 (es) 2009-02-04
EP2099463A4 (fr) 2010-04-21
CL2007003193A1 (es) 2008-07-04
JP2015110642A (ja) 2015-06-18
US8887721B2 (en) 2014-11-18
TW200836752A (en) 2008-09-16
EP2099463B1 (fr) 2014-07-16
KR20140088908A (ko) 2014-07-11
JP5697335B2 (ja) 2015-04-08
CN101573125A (zh) 2009-11-04
TWI474824B (zh) 2015-03-01
KR101548692B1 (ko) 2015-09-01
KR20090087900A (ko) 2009-08-18
JP2010509353A (ja) 2010-03-25
EP2514473A1 (fr) 2012-10-24
WO2008063868A3 (fr) 2008-09-18
JP6095709B2 (ja) 2017-03-15

Similar Documents

Publication Publication Date Title
HK1134455A1 (en) Attenuation of vasoactive oxygen carrier-induced vasoconstriction
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
EP2063941A4 (fr) Détermination d'une fuite pendant un traitement cpap
IL193587A0 (en) Heterobicyclic pyrazole compounds and methods of use
EP2068864A4 (fr) Utilisations thérapeutiques d'urolithines
EP2046174A4 (fr) Structure de couche de revêtement pour appareil de cuisson par chaleur
EP2026843A4 (fr) Utilisations thérapeutiques d'inhibiteurs de rtp801l
EP2023718A4 (fr) Composés de ligand de créatine et procédés d'utilisation correspondants
EP2046489A4 (fr) Traitement de membranes au monopersulfate amélioré
AU2007228570A8 (en) Treatment of CNS conditions
ZA200810234B (en) Benzimidazole modulators of vr1
EP2094085A4 (fr) Composés anti-cholestérolémiants et procédés d'utilisation
EP2032131A4 (fr) Procédé de traitement
GB0812342D0 (en) Modulators of hypoxia inducible factor-1 and related uses
EP2222764A4 (fr) Contrôle de l'épaisseur d'une couche résiduelle
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
GB0610746D0 (en) Method of treatment
EP2088111A4 (fr) Amortisseur d'ascenseur
GB0619500D0 (en) Treatment of fibrosis
IL197966A0 (en) Use of modified cyclosporin
GB0624570D0 (en) Floating port and method of use
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
EP2086560A4 (fr) Procédés de traitement de l'épiphora
ZA200903445B (en) Use of carrageenan for treating rhinovirus infections
GB0720429D0 (en) Treatment of contaminated gases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201106